Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer

Sex: Female

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: NA

Enrollment: 86

Sponsor: Wenjin Yin

Location: Renji Hospital, School of Medicine, Shanghai Jiaotong University Shanghai

Summary

To compare the efficacy and safety of capecitabine and cyclophosphamide (XC) versus physician's choice as maintenance therapy for patients with advanced breast cancer who achieved disease control after salvage treatment.

Eligibility Criteria

Inclusion Criteria: * Female, age≥18 years old * ECOG≤2 * Pathologically confirmed primary breast cancer, with pathologically or radiologically confirmed recurrent or metastatic lesions * HR+/HER2+ or HR-/HER2+ or HR-/HER2- * At least one measurable lesion or bone-only disease (osteolytic or mixed) according to RECIST v1.1 * Disease control (complete response + partial response + stable disease) after salvage treatment * Expected survival ≥6 months * Adequate organ function Exclusion Criteria: * during pregnancy and lactation * Patients with central nervous system metastasis

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05876065). StuddyBuddy aggregates publicly available trial information.